Martin Heidecker

Martin joined the Boehringer Ingelheim Venture Fund in 2010 to invest in early innovative therapeutic life science companies. In October 2013, Martin established the US-office of BIVF in Cambridge, MA, where he is focusing on biotech seed-investments. He has 15 years of investing and commercial experience in both venture capital and global pharma companies. He serves as board member of AMP Therapeutics in Leipzig, ArmaGen in Calabasas, 121bio in Cambridge and Sentien in Medford.

Prior to BIVF, Martin held several global roles in Marketing at Boehringer Ingelheim and Solvay Pharmaceuticals and was involved in the global launch of several products in the area of CNS. Martin began his career as an Investment Manager at Bayern Kapital, focusing on seed investments of biotech companies. Martin holds a PhD in Biology as well as a Master degree in Biology and Economics. He serves on the board of AMP Therapeutics GmbH and ArmaGen Technologies, Inc.

Dr. Martin Heidecker

Martin Heidecker

Contact Venture Fund